No official summary available for this bill.
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7391 Introduced in House (IH)]
<DOC>
119th CONGRESS
2d Session
H. R. 7391
To amend title III of the Public Health Service Act to ensure that
Federally-qualified health centers are not required to pay more than
the 340B ceiling price for covered outpatient drugs at the time of
purchase.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
February 5, 2026
Mr. Bergman (for himself, Mr. Auchincloss, Mr. Moulton, Mr. Lynch, Mr.
Smucker, Ms. Lois Frankel of Florida, Ms. Norton, Mr. Mann, Mr. Mrvan,
Ms. Balint, Ms. Davids of Kansas, Ms. Maloy, Mr. Bresnahan, Mr.
Cleaver, Ms. Ansari, Mr. Huizenga, Ms. McBride, Ms. Titus, Ms. Tlaib,
Mr. Neguse, Mr. Crank, Ms. Lee of Nevada, Mr. Lucas, Mr. Larsen of
Washington, and Mr. Cohen) introduced the following bill; which was
referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To amend title III of the Public Health Service Act to ensure that
Federally-qualified health centers are not required to pay more than
the 340B ceiling price for covered outpatient drugs at the time of
purchase.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Community Health Center Drug Pricing
Protection Act''.
SEC. 2. ENSURING UPFRONT 340B DISCOUNTED PRICING FOR FEDERALLY-
QUALIFIED HEALTH CENTERS.
(a) In General.--Section 340B(a) of the Public Health Service Act
(42 U.S.C. 256b(a)) is amended by adding at the end the following new
paragraph:
``(11) Upfront discounted pricing for federally-qualified
health centers.--The Secretary may not enter into an agreement
with a manufacturer of covered outpatient drugs under paragraph
(1) under which the amount required to be paid to the
manufacturer for covered outpatient drugs by a covered entity
described in paragraph (4)(A) exceeds, at the point of purchase
of such drug, the applicable ceiling price for such drug (as
described in paragraph (1)).''.
(b) Rule of Construction.--Nothing in this section, or the
amendment made by this section, shall be construed to permit under
paragraph (1) of section 340B(a) of the Public Health Service Act (42
U.S.C. 256b(a)) any arrangement under which a covered entity described
in paragraph (4)(A) of such section pays to the manufacturer of a
covered outpatient drug an amount in excess of the applicable ceiling
price for such drug (as described in such paragraph (1)) at the time of
purchase, with later reconciliation by rebate, reimbursement, or other
payment.
(c) Effective Dates.--
(1) In general.--The amendments made by this section shall
take effect on the date of the enactment of this section and
shall apply to drugs purchased on or after the date of the
enactment of this section.
(2) Application to existing agreements.--Beginning on the
date of the enactment of this section, the amendments made by
this section shall be taken into account in determining whether
an agreement with a manufacturer of covered outpatient drugs
meets the requirements of section 340B(a) of the Public Health
Service Act (42 U.S.C. 256b(a)).
<all>
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line